Home > Insider Trading > Filing (0001209191-18-056072)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1169245	Phasebio Pharmaceuticals Inc	PHAS	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1005561	J Peter Barris	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No
1219855	James M Barrett	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No
1219871	M David Mott	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No
1235112	J Patrick Kerins	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No
1237289	D Scott Sandell	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No
1277631	Forest Baskett	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No
1452907	New Enterprise Associates 13 Lp	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No
1460751	Nea 13 Gp, Ltd	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No
1460752	Nea Partners 13, Limited Partnership	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No
1479386	Ravi Viswanathan	1954 Greenspring Drive Suite 600 Timonium MD 21093	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-10-22	4,841,634	$0.00	4,841,634	No	4	C	Indirect	See Note 2
Common Stock	Acquisiton	2018-10-22	1,800,000	$5.00	6,641,634	No	4	P	Indirect	See Note 2

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Note 2
No	4	P	Indirect	See Note 2

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Series B Preferred Stock	Warrants to Purchase Series B Preferred Stock	Disposition	2018-10-22	49,030	$0.00	49,030	$0.12
Common Stock	Series B Preferred Stock	Acquisiton	2018-10-22	49,030	$0.12	49,030	$0.00
Common Stock	Series B Preferred Stock	Disposition	2018-10-22	1,177	$5.00	1,177	$0.00
Common Stock	Series B Preferred Stock	Disposition	2018-10-22	3,279,627	$0.00	3,279,627	$0.00
Series C-1 Preferred Stock	Warrants to Purchase Series C-1 Preferred Stock	Disposition	2018-10-22	181,190	$0.00	181,190	$0.12
Common Stock	Series C-1 Preferred Stock	Acquisiton	2018-10-22	181,190	$0.12	181,190	$0.00
Common Stock	Series C-1 Preferred Stock	Disposition	2018-10-22	4,349	$5.00	4,349	$0.00
Common Stock	Series C-1 Preferred Stock	Disposition	2018-10-22	437,706	$0.00	437,706	$0.00
Common Stock	Series D Preferred Stock	Disposition	2018-10-22	1,124,301	$0.00	1,124,301	$0.00

Remaning Holdings	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	No	4	X	Indirect
3,280,804	No	4	X	Indirect
3,279,627	No	4	S	Indirect
0	No	4	C	Indirect
0	No	4	X	Indirect
442,055	No	4	X	Indirect
437,706	No	4	S	Indirect
0	No	4	C	Indirect
0	No	4	C	Indirect

Footnotes

Each share of Preferred Stock converted into Common Stock on a one-for-one basis upon the closing of the Issuer's initial public offering and has no expiration date.
The securities are directly held by New Enterprise Associates 13, L.P. ("NEA 13") and are indirectly held by NEA Partners 13, L.P. ("NEA Partners 13"), the sole general partner of NEA 13, NEA 13 GP, LTD ("NEA 13 LTD"), the sole general partner of NEA Partners 13 and each of the individual directors of NEA 13 LTD (NEA Partners 13, NEA 13 LTD and the individual directors of NEA 13 LTD (collectively, the "Directors") together, the "Indirect Reporting Persons"). The Directors of NEA 13 LTD are M. James Barrett, Peter J. Barris, Forest Baskett, Patrick J. Kerins, David M. Mott, Scott D. Sandell and Ravi Viswanathan. The Indirect Reporting Persons disclaim beneficial ownership within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the NEA 13 securities in which the Indirect Reporting Persons have no pecuniary interest.
Represents the net exercise of the warrants immediately prior to, and contingent upon, the closing of the Issuer's initial public offering.
The warrants were exercisable until, and were scheduled to expire upon, the closing of the Issuer's initial public offering.